ADUS vs. USPH: Which Stock Should Value Investors Buy Now?

A comparison of Medical - Outpatient and Home Healthcare stocks Addus HomeCare (ADUS) and U.S. Physical Therapy (USPH) for value investors indicates ADUS as the superior choice. ADUS holds a Zacks Rank of #2 (Buy) compared to USPH's #3 (Hold), suggesting a more favorable earnings outlook. Furthermore, ADUS presents more attractive valuation metrics, including a forward P/E of 18.22 (vs. USPH's 31.94), a PEG ratio of 1.43 (vs. 3.85), and a P/B ratio of 2.04 (vs. 2.42), resulting in a Zacks Value Grade of B for ADUS versus C for USPH. This comprehensive analysis positions ADUS as the preferred value investment opportunity.

Analysis

A comparative analysis between Addus HomeCare (ADUS) and U.S. Physical Therapy (USPH) within the medical outpatient and home healthcare sector reveals a distinct preference for ADUS based on key value and momentum indicators. ADUS holds a Zacks Rank of #2 (Buy), signifying stronger positive earnings estimate revisions and an improving earnings outlook compared to USPH's #3 (Hold) rating. This fundamental strength is reinforced by a superior valuation profile. ADUS trades at a forward P/E ratio of 18.22, significantly lower than USPH's 31.94. Furthermore, its PEG ratio of 1.43 is substantially more attractive than USPH's 3.85, indicating a more reasonable price relative to its expected earnings growth. The value case is further supported by a lower Price-to-Book ratio for ADUS at 2.04 versus 2.42 for USPH. Cumulatively, these metrics result in ADUS earning a Zacks Value grade of 'B', while USPH receives a 'C', positioning ADUS as the more compelling opportunity for value-focused investors according to this framework.

Key Decisions for Investors

• Value-oriented investors should consider Addus HomeCare (ADUS) as the more attractive investment, given its superior Zacks rank and more favorable valuation metrics including P/E, PEG, and P/B ratios.
• Investors holding U.S. Physical Therapy (USPH) should note its considerably higher valuation and neutral 'Hold' rating, suggesting potential underperformance relative to peers like ADUS.
• For those seeking exposure to the home healthcare space, the data suggests a clear preference for ADUS over USPH an a relative value basis due to its stronger earnings revision momentum and more attractive pricing.